(210113) -- JAKARTA, Jan. 13, 2021 -- Indonesian President Joko Widodo receives the COVID-19 vaccine shot developed by China s biopharmaceutical company Sinovac Biotech at Presidential Palace in Jakarta, Indonesia, Jan. 13, 2021. The president, widely known as Jokowi, is the first Indonesian vaccinated to show that the vaccine is safe. ( Presidential Press Bureau Handout via Xinhua) INDONESIA-JAKARTA-PRESIDENT-VACCINE-COVID-19 AgusxSuparto

(210113) -- JAKARTA, Jan. 13, 2021 -- Indonesian President Joko Widodo receives the COVID-19 vaccine shot developed by China s biopharmaceutical company Sinovac Biotech at Presidential Palace in Jakarta, Indonesia, Jan. 13, 2021. The president, widely known as Jokowi, is the first Indonesian vaccinated to show that the vaccine is safe. ( Presidential Press Bureau Handout via Xinhua) INDONESIA-JAKARTA-PRESIDENT-VACCINE-COVID-19 AgusxSuparto

Choose your license

Rights Managed:

One-time editorial use in an online article, social media channels, internal presentation, website, newsletter, or blog.

One-time editorial use in a book, newspaper or magazine (excluding cover page), external presentation. Limited to 5,000 circulation. This includes the rights available in the Standard license.

Media Info

Credit: Xinhua

Media ID:

Recording Date: Jan 13, 2021

Media Size: 5,217×7,715 Pixels

(210113) -- JAKARTA, Jan. 13, 2021 -- Indonesian President Joko Widodo receives the COVID-19 vaccine shot developed by China s biopharmaceutical company Sinovac Biotech at Presidential Palace in Jakarta, Indonesia, Jan. 13, 2021. The president, widely known as Jokowi, is the first Indonesian vaccinated to show that the vaccine is safe. ( Presidential Press Bureau Handout via Xinhua) INDONESIA-JAKARTA-PRESIDENT-VACCINE-COVID-19 AgusxSuparto

Restrictions: This image can not be published in China.

Release Info: Do I need a release?

Captions may have been translated or enriched by an AI system.
For more information about AI-assisted captions, see AI-assisted captions.

Need a custom license?

If your intended use isn't covered by the available options (such as non-editorial purposes or specific distribution needs), contact us. Our team will be happy to provide a tailored offer based on your requirements.